Sepsis Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

DelveInsight's "Sepsis Drugs Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Sepsis, historical and forecasted epidemiology as well as the Sepsis market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Sepsis Market Size @ Sepsis Market Outlook- https://www.delveinsight.com/sample-request/sepsis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Sepsis Market Size Report
• In May 2025, Regeneron Pharmaceuticals conducted a study is researching an experimental drug called REGN7544 (called "study drug"). The study is focused on adult patients (18 to 85 years) hospitalized due to a serious infection (called "sepsis") and receiving standard-of-care medications for low blood pressure (called "vasopressors") due to sepsis.
• In May 2025, Novartis Pharmaceuticals organized a study was to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profile and to evaluate the safety and tolerability of TIN816 in hospitalized adult participants in an intensive care setting with a diagnosis of sepsis-associated acute kidney injury (SA-AKI).
• Among 7MM, the United States accounted for the maximum share of the Sepsis population, with above 55% in 2023.
• In EU4 and the UK, Germany accounted for the highest number of incident cases in 2023.
• As per analysis, it is notable that in the 7MM, the majority of the patient pool was males as compared to females, whereas in the US female population dominated the Sepsis incident pool..
• According to Delveinsight, approximately 57% of all cases were sepsis without organ dysfunction, followed by septic shock (24%) and severe sepsis (18%) in the United States in 2023. These cases are expected to increase during the forecast period (2024-2034).
• As per the analysis, lung infection, UTI infection, gut infection, and skin infection are the leading four infection sites in patients with sepsis, accounting for approximately 43%, 30%, 13%, and 13%, respectively of all sites of infection.
• The leading Sepsis Companies such as La Jolla Pharmaceuticals, Par Pharmaceutical, Ono Pharmaceutical, Vivacelle Bio, Inotrem, Enlivex Therapeutics, Adrenomed, Shionogi, Asahi Kasei Pharma Corp., AM-Pharma, ABIONYX Pharma, Revimmune, Baxter Healthcare Corporation, BioMarck Pharmaceuticals, and others.
• Promising Sepsis Pipeline Therapies such as Alirocumab, Imipenem, Cilastatin and Relebactam, Cefiderocol, SBI-101, Ceftobiprole medocaril, VBI-S, and others.

Stay ahead in the Sepsis Treatment Market Size with DelveInsight's Strategic Report @ Sepsis Therapeutics Market Report- https://www.delveinsight.com/sample-request/sepsis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Sepsis Epidemiology Segmentation in the 7MM
• Total Sepsis Incidence cases
• Sepsis Gender-specific Incidence Cases
• Sepsis Severity-specific Incidence cases
• Origin-specific Sepsis Incidence cases

Download the report to understand which factors are driving Sepsis Epidemiology trends @ Sepsis Prevalence- https://www.delveinsight.com/sample-request/sepsis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Sepsis Marketed Drugs
• GIAPREZA (angiotensin II): La Jolla Pharmaceuticals/Innoviva Specialty Therapeutics
GIAPREZA (angiotensin II) (La Jolla Pharmaceuticals/Innoviva Specialty Therapeutics) injection is approved by the US FDA in December 2017 as a vasoconstrictor to increase blood pressure in adults with septic or other distributive shocks. The drug is also approved by the European Commission in 2019 to treat refractory hypotension in adults with septic or other distributive shocks who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. The drug mimics the body's endogenous angiotensin II peptide, which is central to the renin-angiotensin-aldosterone system, which regulates blood pressure.

• Onoact Injection (Landiolol hydrochloride): Ono Pharmaceuticals
Onoact is a short-acting β1 blocker that selectively blocks β1 receptors mainly found in the heart. It is for emergency treatment of intra-operative or post-operative tachyarrhythmia (atrial fibrillation, atrial flutter, sinus tachycardia) and treatment of tachyarrhythmia in left ventricular dysfunction (atrial fibrillation, atrial flutter). In June 2022, Onoact received approval for intravenous infusion 50mg/150mg, for the additional indication of tachyarrhythmia (atrial fibrillation, atrial flutter, and sinus tachycardia) associated with sepsis for a partial change in the approved items of the manufacturing and marketing approval in Japan.

Sepsis Emerging Drugs
• VBI-S: Vivacelle Bio
Vivacelle Bio's lead candidate, VBI-S is made of small particles of specific lipid called micelles and liposomes to treat hypotension. VBI-S is an intravenously injectable fluid comprised of phospholipid nanoparticles that were specifically designed to shift the biophysical properties of the 'body's fluid volume in hypovolemic shock, due to sepsis, from non-survival to survival. In July 2019, the company announced US FDA clearance to enroll patients into a Phase IIa Sepsis Clinical Trials of VBI-S to elevate blood pressure in subjects who have shock due to sepsis, later met 100% endpoints in Phase II. The therapy is currently under Phase III clinical evaluation to treat hypovolemia due to sepsis/septic shock.

• Nangibotide: Inotrem
Inotrem's Nangibotide is a synthetic peptide and first-in-class TREM-1 inhibitor. Nangibotide blocks the TREM-1-mediated immune dysregulations in sterile or infectious acute inflammatory syndromes. The drug restores a balanced inflammatory response and improves outcomes, particularly in those patients with high levels of TREM-1 pathway activation. The drug is currently under Phase II for the treatment of septic shock. This lead candidate has been granted EMA's PRIority MEdicines (PRIME) scheme, and was also granted Fast-track status by the FDA for septic shock.

To learn more about Sepsis treatment guidelines, visit @ Sepsis Treatment Market Landscape- https://www.delveinsight.com/sample-request/sepsis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Sepsis Companies
La Jolla Pharmaceuticals, Par Pharmaceutical, Ono Pharmaceutical, Vivacelle Bio, Inotrem, Enlivex Therapeutics, Adrenomed, Shionogi, Asahi Kasei Pharma Corp., AM-Pharma, ABIONYX Pharma, Revimmune, Baxter Healthcare Corporation, BioMarck Pharmaceuticals, and others.

Sepsis Market Outlook
Sepsis is a complex disease, which not only involves a wide array of causative agents but also results in different individual immune responses, causing various single or multiple organ dysfunction. Treatment for sepsis varies, depending on the site and the cause of the initial infection, the organs affected and the extent of any damage. Sepsis should be treated as a medical emergency and treated as quickly and efficiently as possible as soon as it has been identified.

Learn more about the FDA-approved drugs for Sepsis @ Drugs for Sepsis Treatment- https://www.delveinsight.com/sample-request/sepsis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Sepsis Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Sepsis Companies- La Jolla Pharmaceuticals, Par Pharmaceutical, Ono Pharmaceutical, Vivacelle Bio, Inotrem, Enlivex Therapeutics, Adrenomed, Shionogi, Asahi Kasei Pharma Corp., AM-Pharma, ABIONYX Pharma, Revimmune, Baxter Healthcare Corporation, BioMarck Pharmaceuticals, and others.
• Sepsis Pipeline Therapies- Alirocumab, Imipenem, Cilastatin and Relebactam, Cefiderocol, SBI-101, Ceftobiprole medocaril, VBI-S, and others.
• Sepsis Market Dynamics: Sepsis Market Drivers and Barriers
• Sepsis Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Sepsis Drugs in development @ Sepsis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/sepsis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1 Key Insights
2 Sepsis Market Report Introduction
3 Sepsis Executive Summary
4 Key Events
5 Sepsis Epidemiology and Market Forecast Methodology
6 Sepsis Market Overview at a Glance
7 Sepsis: Disease Background and Overview
8 Sepsis Treatment and Medical Management
9 Sepsis Epidemiology and Patient Population of Sepsis
10 Sepsis Patient Journey
11 Sepsis Marketed Drugs
12 Key Cross Competition
13 Key Sepsis Emerging Therapies
14 Sepsis: Seven Major Market Analysis
15 Sepsis KOL Views
16 Sepsis SWOT Analysis
17 Sepsis Unmet Needs
18 Sepsis Market Access and Reimbursement
19 Appendix
20 DelveInsight Capabilities
21 Disclaimer
22 About DelveInsight

List of Top Selling Market Research Reports in 2025

CAR-T Pipeline- https://www.delveinsight.com/report-store/car-t-pipeline-insight
Cystic Fibrosis Market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Indwelling Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Ly3454738 Drug Insight- https://www.delveinsight.com/report-store/moderate-to-severe-atopic-dermatitis-pipeline-insight
NK Cell Therapy Market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Periodontal Disease Market- https://www.delveinsight.com/report-store/periodontal-disease-market
Scoliosis Market- https://www.delveinsight.com/report-store/scoliosis-market
Urea Cycle Disorders Market- https://www.delveinsight.com/report-store/urea-cycle-disorders-pipeline-insight
Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Cardiac Implantable Electronic Devices Market- https://www.delveinsight.com/report-store/cardiac-implantable-electronic-devices-cieds-market
Positive Airway Pressure Device Market- https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Surgical Energy Instruments Market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market
Total Knee Arthroplasty Market- https://www.delveinsight.com/report-store/knee-reconstruction-devices-market
Healthcare Competitive Benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Lice Infestations Market- https://www.delveinsight.com/report-store/lice-infestations-pipeline-insight
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Sepsis Market- https://www.delveinsight.com/report-store/sepsis-market-insight
Surgical Mask & Respirator Market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.